BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19504183)

  • 1. Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer.
    Ameziane N; van den Ouweland AM; Adank MA; Vijzelaar RN; Errami A; Dorsman JC; Joenje H; Meijers-Heijboer H; Waisfisz Q
    Breast Cancer Res Treat; 2009 Dec; 118(3):651-3. PubMed ID: 19504183
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
    Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
    Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
    Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
    Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
    McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
    Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.
    Frank B; Hemminki K; Meindl A; Wappenschmidt B; Sutter C; Kiechle M; Bugert P; Schmutzler RK; Bartram CR; Burwinkel B
    BMC Cancer; 2007 May; 7():83. PubMed ID: 17504528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovering moderate-risk breast cancer susceptibility genes.
    Hollestelle A; Wasielewski M; Martens JW; Schutte M
    Curr Opin Genet Dev; 2010 Jun; 20(3):268-76. PubMed ID: 20346647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomedicine. D-Day for BRCA2.
    Witt E; Ashworth A
    Science; 2002 Jul; 297(5581):534. PubMed ID: 12065747
    [No Abstract]   [Full Text] [Related]  

  • 15. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
    Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
    Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
    Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
    Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.